A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR)
- 23 August 2014
- journal article
- case report
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 28 (2) , 251-254
Abstract
In myeloma cast nephropathy, fast reduction of serum free light chain (FLC) levels correlates with renal recovery. Recently, extracorporeal treatments using filters with a high-molecular weight cut-off have been successfully used for FLC removal. However, using these new filters, high cost and elevated albumin leakage are common drawbacks. We studied a new and cheaper therapeutic approach with adsorbent resins to evaluate its efficacy. We treated four patients, affected by dialysis-dependent acute kidney injury (AKI) due to biopsy proven de novo FLC myeloma cast nephropathy. Each patient underwent bortezomib chemotherapy and extracorporeal treatment with the supra-hemodiafiltration with endogenous reinfusion (HFR) technique (Supra-HFR, Bellco Mirandola, Modena, Italy). Supra-HFR is a kind of hemodiafiltration that utilizes separated convection, diffusion and adsorption. The sorbent cartridge has a high affinity for FLC (both κ and λ) but is able to re-infuse albumin, avoiding the need for albumin perfusions. Supra HFR treatments (4 h each) were carried out for eight consecutive days and then every other day. All patients showed a significant reduction of serum FLC, whereas serum albumin concentration remained unchanged. Renal function recovered in three out of four patients. FLC removal with adsorbent resins represents an effective therapeutic strategy that does not require replacement with albumin .Keywords
This publication has 10 references indexed in Scilit:
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 TrialJournal of Clinical Oncology, 2012
- Novel approaches for reducing free light chains in patients with myeloma kidneyNature Reviews Nephrology, 2012
- Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II StudyJournal of Clinical Oncology, 2010
- VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA StudyJournal of Clinical Oncology, 2009
- Efficient Removal of Immunoglobulin Free Light Chains by Hemodialysis for Multiple MyelomaJournal of the American Society of Nephrology, 2007
- Hemodiafiltration with Endogenous Reinfusion2007
- Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myelomaBritish Journal of Haematology, 2005
- [Optimization of a HFR sorbent cartridge for high molecular weight uremic toxins].2005
- Choosing New Adsorbents for Endogenous Ultrapure Infusion Fluid: Performances, Safety and Flow DistributionThe International Journal of Artificial Organs, 2001
- Single Compartment Models for Evaluating β2-Microglobulin Clearance During HemodialysisASAIO Journal, 1997